120 related articles for article (PubMed ID: 34854137)
1. Combination of two monoclonal antibodies with SOCS1 N- and C-terminal binding sites to address SOCS1 status in B cells and B-cell lymphoma.
Weissinger SE; Zahn M; Marienfeld R; Tessmer C; Moldenhauer G; Möller P
Eur J Haematol; 2022 Mar; 108(3):223-231. PubMed ID: 34854137
[TBL] [Abstract][Full Text] [Related]
2. A new reliable and highly specific monoclonal antibody to detect the C-terminal region of silencer of cytokine signaling 1.
Weissinger SE; Zahn M; Marienfeld R; Tessmer C; Moldenhauer G; Möller P
Eur J Haematol; 2021 Jul; 107(1):74-80. PubMed ID: 33714214
[TBL] [Abstract][Full Text] [Related]
3. Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities.
Mottok A; Renné C; Seifert M; Oppermann E; Bechstein W; Hansmann ML; Küppers R; Bräuninger A
Blood; 2009 Nov; 114(20):4503-6. PubMed ID: 19734449
[TBL] [Abstract][Full Text] [Related]
4. Structural analysis and conformational dynamics of SOCS1 gene mutations involved in diffuse large B-cell lymphoma.
Dristy TT; Noor AR; Dey P; Saha A
Gene; 2023 May; 864():147293. PubMed ID: 36813059
[TBL] [Abstract][Full Text] [Related]
5. SOCS1 mutation subtypes predict divergent outcomes in diffuse large B-Cell lymphoma (DLBCL) patients.
Schif B; Lennerz JK; Kohler CW; Bentink S; Kreuz M; Melzner I; Ritz O; Trümper L; Loeffler M; Spang R; Möller P
Oncotarget; 2013 Jan; 4(1):35-47. PubMed ID: 23296022
[TBL] [Abstract][Full Text] [Related]
6. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
[TBL] [Abstract][Full Text] [Related]
7. Suppressor of cytokine signaling 1 gene mutation status as a prognostic biomarker in classical Hodgkin lymphoma.
Lennerz JK; Hoffmann K; Bubolz AM; Lessel D; Welke C; Rüther N; Viardot A; Möller P
Oncotarget; 2015 Oct; 6(30):29097-110. PubMed ID: 26336985
[TBL] [Abstract][Full Text] [Related]
8. The impact of SOCS1 mutations in diffuse large B-cell lymphoma.
Mellert K; Martin M; Lennerz JK; Lüdeke M; Staiger AM; Kreuz M; Löffler M; Schmitz N; Trümper L; Feller AC; Hartmann S; Hansmann ML; Klapper W; Stein H; Rosenwald A; Ott G; Ziepert M; Möller P
Br J Haematol; 2019 Dec; 187(5):627-637. PubMed ID: 31407320
[TBL] [Abstract][Full Text] [Related]
9.
Schuhmacher B; Bein J; Rausch T; Benes V; Tousseyn T; Vornanen M; Ponzoni M; Thurner L; Gascoyne R; Steidl C; Küppers R; Hansmann ML; Hartmann S
Haematologica; 2019 Feb; 104(2):330-337. PubMed ID: 30213827
[TBL] [Abstract][Full Text] [Related]
10. Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer.
Sasi W; Jiang WG; Sharma A; Mokbel K
BMC Cancer; 2010 Apr; 10():178. PubMed ID: 20433750
[TBL] [Abstract][Full Text] [Related]
11. Suppressor of cytokine signaling 1 regulates embryonic myelopoiesis independently of its effects on T cell development.
O'Sullivan LA; Noor SM; Trengove MC; Lewis RS; Liongue C; Sprigg NS; Nicholson SE; Ward AC
J Immunol; 2011 Apr; 186(8):4751-61. PubMed ID: 21421851
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation of SOCS1/2/3 predicts hepatocellular carcinoma recurrence after liver transplantation.
Yang Z; Zhu H; Zhang L; Wei Q; Zhou L; Xu X; Song P; Liu J; Xie H; Zheng S
Mol Biol Rep; 2020 Mar; 47(3):1773-1782. PubMed ID: 32006198
[TBL] [Abstract][Full Text] [Related]
13. Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6.
Mottok A; Renné C; Willenbrock K; Hansmann ML; Bräuninger A
Blood; 2007 Nov; 110(9):3387-90. PubMed ID: 17652621
[TBL] [Abstract][Full Text] [Related]
14. Suppressor of cytokine signaling 1 (SOCS1) limits NFkappaB signaling by decreasing p65 stability within the cell nucleus.
Strebovsky J; Walker P; Lang R; Dalpke AH
FASEB J; 2011 Mar; 25(3):863-74. PubMed ID: 21084693
[TBL] [Abstract][Full Text] [Related]
15. Gene polymorphisms of SOCS1 and SOCS2 and acute lymphoblastic leukemia.
Chen SS; Wu WZ; Zhang YP; Huang WJ
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5564-5572. PubMed ID: 32495891
[TBL] [Abstract][Full Text] [Related]
16. Homozygous deletion of SOCS1 in primary mediastinal B-cell lymphoma detected by CGH to BAC microarrays.
Mestre C; Rubio-Moscardo F; Rosenwald A; Climent J; Dyer MJ; Staudt L; Pinkel D; Siebert R; Martinez-Climent JA
Leukemia; 2005 Jun; 19(6):1082-4. PubMed ID: 15815722
[No Abstract] [Full Text] [Related]
17. The IFN-gamma-dependent suppressor of cytokine signaling 1 promoter activity is positively regulated by IFN regulatory factor-1 and Sp1 but repressed by growth factor independence-1b and Krüppel-like factor-4, and it is dysregulated in psoriatic keratinocytes.
Madonna S; Scarponi C; Sestito R; Pallotta S; Cavani A; Albanesi C
J Immunol; 2010 Aug; 185(4):2467-81. PubMed ID: 20644166
[TBL] [Abstract][Full Text] [Related]
18. Suppressor of cytokine signaling-1 regulates inflammatory bowel disease in which both IFNgamma and IL-4 are involved.
Chinen T; Kobayashi T; Ogata H; Takaesu G; Takaki H; Hashimoto M; Yagita H; Nawata H; Yoshimura A
Gastroenterology; 2006 Feb; 130(2):373-88. PubMed ID: 16472593
[TBL] [Abstract][Full Text] [Related]
19. Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer.
Chevrier M; Bobbala D; Villalobos-Hernandez A; Khan MG; Ramanathan S; Saucier C; Ferbeyre G; Geha S; Ilangumaran S
BMC Cancer; 2017 Feb; 17(1):157. PubMed ID: 28235401
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic alteration of the SOCS1 gene in hepatocellular carcinoma.
Chu PY; Yeh CM; Hsu NC; Chang YS; Chang JG; Yeh KT
Swiss Med Wkly; 2010; 140():w13065. PubMed ID: 20648401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
